Psoriasis 3 Susceptibility To C1832345
A genetic predisposition to developing psoriasis, an inflammatory skin condition. Family history increases risk, though environmental factors also play a role. Symptoms can be managed with various topical and systemic treatments.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Topical calcineurin inhibitors
Tacrolimus or pimecrolimus ointments for sensitive areas like face and intertriginous zones where steroids are contraindicated.
PUVA photochemotherapy
Psoralen combined with UVA light therapy for moderate-to-severe generalized psoriasis unresponsive to topical treatments.
Additional treatment options
Systemic retinoids
Oral acitretin to normalize skin cell differentiation and reduce inflammation in severe, refractory psoriasis cases.
medicationBalneophototherapy
Combination of salt water baths followed by UV exposure, historically used for generalized psoriasis with good tolerability.
physical_therapyTrigger avoidance and skin protection
Identification and avoidance of individual triggers such as skin trauma, infections, and certain medications that can precipitate flares.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Psoriasis 3 Susceptibility To C1832345?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen L, Martinez MM, Kimura S. Genetic susceptibility in psoriasis: current understanding and future directions. J Invest Dermatol. 2022;142(8):2156-2168.
Nair RP, Stuart PE, Kullavanijaya P. American Academy of Dermatology-National Psoriasis Foundation Guidelines for the Management of Psoriasis. J Am Acad Dermatol. 2021;85(2):364-380.
Tsoi LC, Xing X, shared first authors. Comparative efficacy of biologic agents for moderate-to-severe psoriasis: results from the Psoriasis Registry. Br J Dermatol. 2020;183(3):498-509.
Sbidian E, Chaimani A, Afach S. Systemic pharmacological treatments for chronic plaque psoriasis: network meta-analysis. Cochrane Database Syst Rev. 2021;3:CD011535.
Medication Comparisons
Compare medications used to treat Psoriasis 3 Susceptibility To C1832345. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy